Apalutamide, an oral selective androgen receptor inhibitor that directly binds to the ligand-binding domain of the androgen receptor, is FDA-approved for treating patients with nonmetastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer. This evidence concerns the gene AR and prostate cancer.